DECABID
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECABID is an oral extended-release small-molecule tablet approved by Eli Lilly in 1989. The mechanism of action and therapeutic indications are not publicly disclosed in available data. Patient population cannot be determined without indication information.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, likely associated with consolidating or defending market share rather than growth-oriented team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DECABID offers minimal career opportunity signals with zero linked job postings, reflecting its late-lifecycle status. Roles available are primarily defensive/managed-market focused rather than growth-oriented, suitable for professionals managing mature-product portfolios at Eli Lilly.
Brand ManagerField Sales Representative
Worked on DECABID at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.